MAP4K7/TNIK

MAP4K7/TNIK is a TRAF2- and NCK-interacting serine/threonine kinase that functions as a regulatory component of the β-catenin-TCF4 transcriptional complex[1]. Mechanistically, TNIK activates Wnt target genes and supports full canonical Wnt/β-catenin transcriptional output[1][2]. In colorectal cancer, TNIK acts downstream of APC loss, making it relevant to APC-mutant Wnt-dependent tumor models[3]. TNIK inhibition suppressed colorectal cancer growth, cancer stemness, and Wnt-driven intestinal tumorigenesis in preclinical models[4]. Compared with related GCK-IV kinases, MAP4K4, MINK1/MAP4K6, and TNIK/MAP4K7 act redundantly in neuronal stress-induced DLK/JNK signaling, so isoform-selective interpretation requires careful experimental design[5]. For experimental applications, NCB-0846, mebendazole-derived OBD9, and ATP-site TNIK inhibitors provide tools to test Wnt transcription, colorectal cancer stemness, EMT, and inhibitor-binding mechanisms[4][6][7][8].